-
Two key presentations by leading KOLs highlight positive results from aXess trials in adult patients with end-stage renal disease who need vascular access to hemodialysis
-
aXess is a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the creation of a new, long-term living vessel
Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announces two presentations on its ground-breaking treatment options during the 46th Annual Charing Cross Symposium, the leading symposium in the field of vascular and endovascular education being held in London from 23rd-25th April 2024.
Revolutionising haemodialysis access: Unveiling the latest advancements from the aXess™ trials
Dr Robert Shahverdyan, Head of Vascular Access Center Hamburg, Germany
Tuesday 23rd April, 11:00am BST
Dr Shahverdyan will be unveiling the latest results from the aXess™ trials, a European single arm feasibility study evaluating the preliminary safety and performance of the aXess™ graft in subjects older than 18 years with end-stage renal disease and deemed unsuitable for fistula creation.
Infection Control Prevention: Infectious challenges, molecular solutions: A glimpse into the future of vascular conduits through supramolecular chemistry
Prof Dr Frans Moll, Department of Vascular Surgery at the University Medical Center in Utrecht, The Netherlands
Thursday 25th April, 10:40am BST
Prof Dr Frans Moll will discuss how the transformative conduits of supramolecular polymer technology have the possibility of significantly reducing infections in multiple clinical applications.
aXess™ is a restorative conduit which enables the creation of a new, long-term living vessel for hemodialysis vascular access.
It combines the safety and patency of an arteriovenous fistula (AVF) with the speed to treatment of an arteriovenous graft (AVG). The aXess™ vascular access conduit offers an improved dialysis patient experience and avoids the frequent reinterventions and complications, such as infections, faced by renal disease patients.
The conference will be attended by Eliane Schutte, CEO, Paulo Neves, CMO and Lucien van Os, COO. If you would like to meet with a member of the team, please get in touch.
Contacts
Xeltis
Eliane Schutte, CEO
Alexander Goemans, CFO
info@xeltis.com
Optimum Strategic Communications
Nick Bastin, Vici Rabbetts, Joshua Evans
+44 (0) 208 078 4357
xeltis@optimumcomms.com
About Xeltis
Xeltis is a medtech company developing transformative implants that enable the natural creation of living and long-lasting vessels and valves. Xeltis’ devices seek to address the limitations of currently available options for the millions of people requiring hemodialysis access grafts or cardiovascular replacements every year.
The Company’s proprietary endogenous tissue restoration (ETR) platform utilizes an advanced polymer implant which regenerates the patient’s own tissue within and around it, before gradually being absorbed and leaving new, living and long-lasting vessels and valves in place. Xeltis’ devices currently under clinical development include aXessTM, implantable blood vessels for hemodialysis vascular access; XABGTM for coronary artery bypass graft (CABG) surgery; and Xplore 2TM for pediatric pulmonary heart valve replacement. Xeltis’ technology has high potential to be applied to other major vascular and cardiovascular diseases and represents a transformative technology for vascular and valve implants.
Xeltis is based in The Netherlands and the USA. Its investors include DaVita Venture Group, EQT Life Sciences, Kurma Partners, VI Partners, and Ysios Capital, as well as Grand Pharma Group and several public and private investors.
About aXess™
aXess™ is a restorative conduit which enables the creation of a new, long-term living vessel for hemodialysis vascular access. It combines the safety and patency of a fistula with the speed to treatment of an AV graft. The aXess™ vascular access conduit offers an improved dialysis patient experience and avoids the frequent reinterventions and complications, such as infections, faced by renal disease patients.
A first-in-human trial of aXess™ demonstrated a significant improvement in performance compared to hemodialysis vascular access solutions. A pivotal trial of aXess™ is currently enrolling up to 110 patients in nine EU countries.
Go to axesspivotal.com for more details.
